Given all of the above, its strange to see the riskiest of sectors, biotech, creeping towards a repair over this past month. Pharma is an obvious safe harbour where pricing power can offset much of your inflationary woes, but biotech, particualrly given the absolute muck that has gone public these past three years from the crossover cartel, should still be in the doghouse surely?
Given all of the above, its strange to see the riskiest of sectors, biotech, creeping towards a repair over this past month. Pharma is an obvious safe harbour where pricing power can offset much of your inflationary woes, but biotech, particualrly given the absolute muck that has gone public these past three years from the crossover cartel, should still be in the doghouse surely?